Literature DB >> 29296877

The role of targeted therapy in the management of patients with AML.

Alexander E Perl1.   

Abstract

Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration's approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulation of daunorubicin/cytarabine (CPX-351/Vyxeos), the standard of care is changing rapidly in AML for subgroups. This review will focus on currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment.

Entities:  

Year:  2017        PMID： 29296877      PMCID： PMC5737125          DOI： 10.1182/bloodadvances.2017009829

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  58 in total

1.  Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Naveen Pemmaraju; Bruno C Medeiros; Hetty E Carraway; Olga Frankfurt; Stephen J Forman; Xuezhong A Yang; Marina Konopleva; Francine Garnache-Ottou; Fanny Angelot-Delettre; Christopher Brooks; Michael Szarek; Eric Rowinsky
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

Authors:  Catherine C Smith; Chao Zhang; Kimberly C Lin; Elisabeth A Lasater; Ying Zhang; Evan Massi; Lauren E Damon; Matthew Pendleton; Ali Bashir; Robert Sebra; Alexander Perl; Andrew Kasarskis; Rafe Shellooe; Garson Tsang; Heidi Carias; Ben Powell; Elizabeth A Burton; Bernice Matusow; Jiazhong Zhang; Wayne Spevak; Prabha N Ibrahim; Mai H Le; Henry H Hsu; Gaston Habets; Brian L West; Gideon Bollag; Neil P Shah
Journal:  Cancer Discov       Date:  2015-04-06       Impact factor: 39.397

3.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

4.  Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.

Authors:  Mark Levis; Patrick Brown; B Douglas Smith; Adam Stine; Rosalyn Pham; Richard Stone; Daniel Deangelo; Ilene Galinsky; Frank Giles; Elihu Estey; Hagop Kantarjian; Pamela Cohen; Yanfeng Wang; Johannes Roesel; Judith E Karp; Donald Small
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

5.  Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.

Authors:  June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steve M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis J Giles
Journal:  Leuk Res       Date:  2006-09-07       Impact factor: 3.156

6.  Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

Authors:  Susan O'Brien; Joseph O Moore; Thomas E Boyd; Loree M Larratt; Aleksander Skotnicki; Benjamin Koziner; Asher A Chanan-Khan; John F Seymour; R Gregory Bociek; Steve Pavletic; Kanti R Rai
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

Review 7.  FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Authors:  Michael R Grunwald; Mark J Levis
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

8.  FLT3 inhibitor-induced neutrophilic dermatosis.

Authors:  Amir T Fathi; Long Le; Robert P Hasserjian; Hossein Sadrzadeh; Mark Levis; Yi-Bin Chen
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113

9.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

10.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585
View more
  17 in total

Review 1.  Immune-Based Therapies in Acute Leukemia.

Authors:  Matthew T Witkowski; Audrey Lasry; William L Carroll; Iannis Aifantis
Journal:  Trends Cancer       Date:  2019-08-29

2.  Radioactive (90Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer.

Authors:  Evgenii L Guryev; Natalia O Volodina; Natalia Y Shilyagina; Sergey V Gudkov; Irina V Balalaeva; Arthur B Volovetskiy; Alexander V Lyubeshkin; Alexey V Sen'; Sergey A Ermilov; Vladimir A Vodeneev; Rem V Petrov; Andrei V Zvyagin; Zhores I Alferov; Sergey M Deyev
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-07       Impact factor: 11.205

3.  Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway.

Authors:  Kaycee B Moshofsky; Hyun J Cho; Guanming Wu; Kyle A Romine; Matthew T Newman; Yoko Kosaka; Shannon K McWeeney; Evan F Lind
Journal:  Blood Adv       Date:  2019-10-22

4.  Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML.

Authors:  Silvia Masciarelli; Ernestina Capuano; Tiziana Ottone; Mariadomenica Divona; Serena Lavorgna; Francesca Liccardo; Martyna Śniegocka; Serena Travaglini; Nelida I Noguera; Alessandra Picardi; Vincenzo Petrozza; Alessandro Fatica; Luca Tamagnone; Maria Teresa Voso; Francesco Lo Coco; Francesco Fazi
Journal:  Blood Adv       Date:  2019-12-23

5.  A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.

Authors:  Leylah M Drusbosky; Neeraj Kumar Singh; Kimberly E Hawkins; Cesia Salan; Madeleine Turcotte; Elizabeth A Wise; Amy Meacham; Vindhya Vijay; Glenda G Anderson; Charlie C Kim; Saumya Radhakrishnan; Yashaswini Ullal; Anay Talawdekar; Huzaifa Sikora; Prashant Nair; Arati Khanna-Gupta; Taher Abbasi; Shireen Vali; Subharup Guha; Nosha Farhadfar; Hemant S Murthy; Biljana N Horn; Helen L Leather; Paul Castillo; Caitlin Tucker; Christina Cline; Leslie Pettiford; Jatinder K Lamba; Jan S Moreb; Randy A Brown; Maxim Norkin; John W Hiemenz; Jack W Hsu; William B Slayton; John R Wingard; Christopher R Cogle
Journal:  Blood Adv       Date:  2019-06-25

Review 6.  Novel Agents for Acute Myeloid Leukemia.

Authors:  Mario Luppi; Francesco Fabbiano; Giuseppe Visani; Giovanni Martinelli; Adriano Venditti
Journal:  Cancers (Basel)       Date:  2018-11-09       Impact factor: 6.639

7.  Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib.

Authors:  Ya-Chen Ko; Chung-Yi Hu; Zheng-Hau Liu; Hwei-Fang Tien; Da-Liang Ou; Hsiung-Fei Chien; Liang-In Lin
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

8.  [The aberrant epigenetic regulation and epigenomic landscape alteration in human acute myelogenous leukemia and the emerged agents that target epigenetic regulators].

Authors:  Z X Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-01-14

9.  Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells.

Authors:  Kathrin Renner; Anton Seilbeck; Nathalie Kauer; Ines Ugele; Peter J Siska; Christina Brummer; Christina Bruss; Sonja-Maria Decking; Matthias Fante; Astrid Schmidt; Kathrin Hammon; Katrin Singer; Sebastian Klobuch; Simone Thomas; Eva Gottfried; Katrin Peter; Marina Kreutz
Journal:  Front Pharmacol       Date:  2018-11-02       Impact factor: 5.810

Review 10.  Nanocarriers as Magic Bullets in the Treatment of Leukemia.

Authors:  Mohammad Houshmand; Francesca Garello; Paola Circosta; Rachele Stefania; Silvio Aime; Giuseppe Saglio; Claudia Giachino
Journal:  Nanomaterials (Basel)       Date:  2020-02-06       Impact factor: 5.076
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.